Is Veeva Systems a Multimillionaire-Maker Stock?
Summarize this article with:
By Prosper Junior Bakiny – Mar 14, 2026 at 4:30PM ESTKey PointsVeeva Systems has produced solid returns since it became public.The company is facing some challenges, notably increased competition. The cloud specialist's strong moat and large addressable market make its outlook attractive. Since its 2013 IPO, Veeva Systems' (VEEV 1.18%) returns have been strong -- the company has posted a compound annual growth rate (CAGR) of 13.6% through this period. However, the stock now faces headwinds, including significant competition in its niche of the cloud market. To turn average investors into multimillionaires, Veeva Systems would need to perform well over a few decades, as it has since 2013. Does the company have what it takes? Image source: Getty Images.
Why Veeva Systems might pull it off Veeva Systems targets the life sciences industry and offers a suite of cloud solutions tailored to its needs. The company chose its niche well: Demand for products like innovative drugs and medical devices will only increase in the long run, along with higher consumer spending and an aging worldwide population. In other words, Veeva operates in an expanding market, which could help it succeed over the long run as it taps into new opportunities. The company's leadership in this corner of the cloud industry is also noteworthy. Veeva Systems' customers include 15 of the top 20 biopharma companies. ExpandNYSE: VEEVVeeva SystemsToday's Change(-1.18%) $-2.13Current Price$178.66Key Data PointsMarket Cap$29BDay's Range$177.95 - $183.5352wk Range$168.13 - $310.50Volume86KAvg Vol2.1MGross Margin76.50% Veeva Systems benefits from switching costs, since its clients depend on its services for critical everyday activities. The stakes are especially high for biotech and pharmaceutical companies that use its platform to help store and manage clinical trial data, protect patient privacy, and comply with the many regulations imposed on corporations in this sector. Veeva Systems' financial results have generally been strong, even though revenue growth has slowed over the years, as it tends to do as companies become more mature. VEEV Revenue (TTM) data by YCharts But the company still sees ample white space ahead. Veeva Systems estimates its current total addressable market at about $20 billion (no doubt this will grow over time, along with the life sciences sector). Meanwhile, the company reported revenue of just $3.2 billion over the trailing-12-month period. Veeva Systems' moat can help it grab a decent share of this remaining market, even as competition intensifies, leading to strong top and bottom-line growth over the next five years and beyond. Don't go all in on one stock It would take a compound annual growth rate of 11.82% to turn a $70,000 investment into $2 million in 30 years. That's slightly less than what Veeva Systems has recorded over the past 13 years, but it is still very competitive and no easy feat to achieve. My view is that Veeva Systems could help investors reach this goal, given its leadership in its core market, strong competitive edge, and slow expansion into newer markets (cosmetics, consumer packaged goods, chemicals) that will take a while to meaningfully impact growth but could pay off down the road. Investors building a well-diversified portfolio designed to achieve strong returns over the long run can add Veeva Systems to their holdings. The company can help such a portfolio turn its owner into a multimillionaire, given enough time and a disciplined approach.Read NextFeb 23, 2026 •By Prosper Junior Bakiny1 Reason I'd Buy Veeva Systems Stock and Never SellNov 13, 2025 •By Prosper Junior Bakiny2 Top Stocks That Can Supercharge Your Portfolio in 2026 and BeyondOct 16, 2025 •By Cory RenauerThis Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare.
But Is It a Buy?Jul 10, 2025 •By Motley Fool YouTubeVeeva Systems: A Strong Contender in Cloud Computing for PharmaMar 5, 2025 •By Motley Fool TranscribingVeeva Systems (VEEV) Q4 2025 Earnings Call TranscriptMar 5, 2025 •By Motley Fool Markets TeamVeeva Systems Q4 Revenue Leaps 14.3%About the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.
Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyStocks MentionedVeeva SystemsNYSE: VEEV$178.66(-1.18%)-$2.13*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.